Think this is the most interesting office I’ve visited in Silicon Valley. Love the board in the background with the names of their investments cycling through.

As we get ready for 2024, let's look back at the Immunity covers of 2023! Thank you to everyone that contributed to the science & art in these beautiful, creative covers! And thanks to everyone who chose Immunity as their niche this year! 😜 What's your favorite cover?

Continued support for the importance of PDL1 pathway inhibition combined with VEGF blockade. An interesting Venn diagram for non-overlapping but related biology between #cancer #immunotherapy and #angiogenesis. Positive trials now in #NSCLC #HCC #RCC #ProstateCancer #endometrial

Awesome post! LOL!

Neoadjuvant chemo/nivo with adjuvant nivo show ⬆️ DFS (HR 0.58) & ⬆️pCR in NSCLC. 23% & 35% didn’t have surgery/adjuvant nivo respectively. Debate about activity of neoadjuvant vs adjuvant vs both is ongoing. No OS. Similar Bladder cancer trials (durva/nivo/pembro) awaited.

Utterly brutal. Deserves 300,000 retweets.

discussant slides on $SMMT #Akeso ivonescimab / $BNTX #Biotheus BNT327 - PM8002 in TNBC, ESG401 TROP2 ADC in HR+/HER2- & TNBC #ESMO24 3/x Dan Chen yuo have another fork of your cancer immunity cycle, via Carmen Criscitiello, incorporating the role of VEGF (& pot. synergy w/ IO)

Genentech, a biotech with a storied past, confronts new turbulence in the present. My story for STAT, based on interviews with former & current employees as well as industry observers statnews.com/2024/09/16/gen…

We all know it's tough out there in biotech land. Down rounds, IPO window shut, Trumpster fires, all of that. But the startups keep coming and there are great people with great science doing great things. We celebrate that every year with the Endpoints 11, and we'd like to hear